Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Low levels of muscarinic M1 receptor–positive neurons in cortical layers III and V in Brodmann areas 9 and 17 from individuals with schizophrenia
Elizabeth Scarr, Shaun Hopper, Valentina Vos, et al.
Journal of Psychiatry and Neuroscience (2018) Vol. 43, Iss. 5, pp. 338-346
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia
Steven M. Paul, Samantha E. Yohn, Michael Popiolek, et al.
American Journal of Psychiatry (2022) Vol. 179, Iss. 9, pp. 611-627
Closed Access | Times Cited: 81
Cholinergic nervous system and glaucoma: From basic science to clinical applications
Muneeb A. Faiq, Gadi Wollstein, Joel S. Schuman, et al.
Progress in Retinal and Eye Research (2019) Vol. 72, pp. 100767-100767
Open Access | Times Cited: 106
A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients
Georgios Schoretsanitis, John M. Kane, Can‐Jun Ruan, et al.
Expert Review of Clinical Pharmacology (2019) Vol. 12, Iss. 7, pp. 603-621
Closed Access | Times Cited: 89
Hippocampal volume and hippocampal neuron density, number and size in schizophrenia: a systematic review and meta-analysis of postmortem studies
Maxwell J. Roeske, Christine Konradi, Stephan Heckers, et al.
Molecular Psychiatry (2020) Vol. 26, Iss. 7, pp. 3524-3535
Open Access | Times Cited: 83
Targeting muscarinic receptors to treat schizophrenia
Daniel J. Foster, Zoey Bryant, P. Jeffrey Conn
Behavioural Brain Research (2021) Vol. 405, pp. 113201-113201
Open Access | Times Cited: 67
Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic
Samantha E. Yohn, Peter J. Weiden, Christian C. Felder, et al.
Trends in Pharmacological Sciences (2022) Vol. 43, Iss. 12, pp. 1098-1112
Open Access | Times Cited: 64
A growing understanding of the role of muscarinic receptors in the molecular pathology and treatment of schizophrenia
Brian Dean, Geor Bakker, Hiroki R. Ueda, et al.
Frontiers in Cellular Neuroscience (2023) Vol. 17
Open Access | Times Cited: 26
Beyond dopamine: Novel strategies for schizophrenia treatment
Paulina Dudzik, Klaudia Lustyk, Karolina Pytka
Medicinal Research Reviews (2024) Vol. 44, Iss. 5, pp. 2307-2330
Closed Access | Times Cited: 13
Psychosis as a disorder of muscarinic signalling: psychopathology and pharmacology
Robert A. McCutcheon, Lilian Weber, Matthew M. Nour, et al.
The Lancet Psychiatry (2024) Vol. 11, Iss. 7, pp. 554-565
Closed Access | Times Cited: 11
Muscarinic M1 and M4 receptors: Hypothesis driven drug development for schizophrenia
Brian Dean, Elizabeth Scarr
Psychiatry Research (2020) Vol. 288, pp. 112989-112989
Closed Access | Times Cited: 56
Novel Compounds in the Treatment of Schizophrenia—A Selective Review
Eva-Maria Tsapakis, Kalliopi Diakaki, Apostolos Miliaras, et al.
Brain Sciences (2023) Vol. 13, Iss. 8, pp. 1193-1193
Open Access | Times Cited: 18
Cholinergic muscarinic M1 and M4 receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders
Daniel Erskine, John‐Paul Taylor, Geor Bakker, et al.
Drug Discovery Today (2019) Vol. 24, Iss. 12, pp. 2307-2314
Closed Access | Times Cited: 43
Abnormal synaptic plasticity and impaired cognition in schizophrenia
Xiulin Wu, Qiujin Yan, Fan Zhu
World Journal of Psychiatry (2022) Vol. 12, Iss. 4, pp. 541-557
Open Access | Times Cited: 23
Imaging the Vesicular Acetylcholine Transporter in Schizophrenia: A Positron Emission Tomography Study Using [18F]-VAT
Jodi J. Weinstein, Scott J. Moeller, Greg Perlman, et al.
Biological Psychiatry (2024) Vol. 96, Iss. 5, pp. 352-364
Closed Access | Times Cited: 4
M1 Muscarinic Receptors Modulate Fear-Related Inputs to the Prefrontal Cortex: Implications for Novel Treatments of Posttraumatic Stress Disorder
James Maksymetz, Max E. Joffe, Sean P. Moran, et al.
Biological Psychiatry (2019) Vol. 85, Iss. 12, pp. 989-1000
Open Access | Times Cited: 32
IUPHAR Review on muscarinic M1 and M4 receptors as drug treatment targets relevant to the molecular pathology of schizophrenia.
Brian Dean
Pharmacological Research (2024) Vol. 210, pp. 107510-107510
Open Access | Times Cited: 3
Distinct Effects of Olanzapine Depot Treatment on Behavior and Muscarinic M1 Receptor Expression in the Triple‐Hit Wisket Rat Model of Schizophrenia
Gyöngyi Horváth, Eszter Ducza, Leatitia Gabriella Adlan, et al.
Genes Brain & Behavior (2025) Vol. 24, Iss. 1
Open Access
Model-based prediction of muscarinic receptor function from auditory mismatch negativity responses
Dario Schöbi, Fabienne Homberg, Stefan Frässle, et al.
NeuroImage (2021) Vol. 237, pp. 118096-118096
Open Access | Times Cited: 22
Auditory mismatch responses are differentially sensitive to changes in muscarinic acetylcholine versus dopamine receptor function
Lilian Weber, Sara Tomiello, Dario Schöbi, et al.
eLife (2022) Vol. 11
Open Access | Times Cited: 15
Lower levels of cortical [3H]pirenzepine binding to postmortem tissue defines a sub-group of older people with schizophrenia with less severe cognitive deficits
Brian Dean, Vahram Haroutunian, Elizabeth Scarr
Schizophrenia Research (2023) Vol. 255, pp. 274-282
Closed Access | Times Cited: 7
Aberrant Hierarchical Prediction Errors Are Associated With Transition to Psychosis: A Computational Single-Trial Analysis of the Mismatch Negativity
Daniel J. Hauke, Colleen E. Charlton, André Schmidt, et al.
Biological Psychiatry Cognitive Neuroscience and Neuroimaging (2023) Vol. 8, Iss. 12, pp. 1176-1185
Open Access | Times Cited: 7
Lower levels of kainate receptors, but not AMPA or NMDA receptors, in Brodmann's area (BA) 9, but not BA 10, from a subgroup of people with schizophrenia who have a marked deficit in cortical muscarinic M1 receptors
Megan Snelleksz, Elizabeth Scarr, Brian Dean
Schizophrenia Research (2024) Vol. 274, pp. 129-136
Closed Access | Times Cited: 2
Widespread Changes in Positive Allosteric Modulation of the Muscarinic M1 Receptor in Some Participants With Schizophrenia
Shaun Hopper, Geoffrey Pavey, Andrea Gogos, et al.
The International Journal of Neuropsychopharmacology (2019) Vol. 22, Iss. 10, pp. 640-650
Open Access | Times Cited: 19
Changes in cortical gene expression in the muscarinic M1 receptor knockout mouse: potential relevance to schizophrenia, Alzheimer’s disease and cognition
Brian Dean, Elizabeth Scarr
Schizophrenia (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 15
Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal
Brian Dean
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 12, pp. 1113-1121
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top